US regulator rejects Lykos’s MDMA therapy, wants more data
Lykos Therapeutics’s ecstasy drug or midomafetamine capsules for the treatment of post-traumatic stress disorder in adults was rejected by the US drug regulatory.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Lykos Therapeutics’s ecstasy drug or midomafetamine capsules for the treatment of post-traumatic stress disorder in adults was rejected by the US drug regulatory.
MDMA-assisted psychotherapy is a breakthrough in the treatment of PTSD, but without proper monitoring and documentation, we are inviting trouble.